Terns’ oral weight-loss drug shows promise in early study, shares jump, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Terns’ ***** weight-loss ***** shows promise in early study, shares jump, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

By Mariam Sunny

Bengaluru: Terns Pharmaceuticals said its ***** obesity ***** reduced weight by an average of 4.9 per cent in an early-stage study, joining drugmakers vying for a share of the lucrative weight-loss treatment market and sending its shares up 27 per cent on Monday.

The experimental treatment, TERN-601, is part of the second generation of weight-loss drugs, which aim to offer a more convenient alternative to injections, under development by companies including Pfizer and Roche.

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The companies are also developing pills, the market for which is expected to hit $150 billion by the early 2030s, according to some analysts.

“We’re very pleased with the totality of the data… seeing in particular, no red flags,” Mizuho analyst Graig Suvannavejh said about Terns’ *****.

The company’s stock was trading at $9.93, and including Monday’s gains, was up more than 50% this year.

Terns said it plans to advance the ***** into mid-stage trials next year.

“We have cash to cover next steps from this program,” CFO Mark Vignola said on a conference call.

Separately, Terns announced it has commenced a proposed stock offering of $125 million of its shares. It intends to use the proceeds to fund development of TERN-601, among other experimental treatments.

TERN-601, which belongs to the GLP-1 class like Wegovy and Zepbound, met the main goals of safety and tolerability in the study, the company said.

A 740-milligram dosage of the once-daily ***** led to an average weight loss of 4.9%, when adjusted for placebo rates, after four weeks of treatment.

BMO Capital Markets analyst Etzer Darout said the once-daily dose is important for the *****’s competitive profile.

In July, Roche’s experimental once-daily pill led to a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage study.

(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar, Sriraj Kalluvila and Shinjini Ganguli)

• Published On Sep 10, 2024 at 06:17 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Terns #***** #weightloss #***** #shows #promise #early #study #shares #jump #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up